GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GTXI
CUSIP40052B10
Phone901-523-9700
Debt
Debt-to-Equity RatioN/A
Current Ratio6.05
Quick Ratio6.05
Price-To-Earnings
Trailing P/E Ratio-10.80
Forward P/E Ratio-10.28
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.78 per share
Price / Book10.68
Profitability
EPS (Most Recent Fiscal Year)($1.75)
Net Income$-30,430,000.00
Net MarginsN/A
Return on Equity-110.72%
Return on Assets-89.83%
Miscellaneous
Employees27
Outstanding Shares24,050,000
Market Cap$441 million
GTX (NASDAQ:GTXI) Frequently Asked Questions
What is GTX's stock symbol?
GTX trades on the NASDAQ under the ticker symbol "GTXI."
How were GTX's earnings last quarter?
GTx, Inc. (NASDAQ:GTXI) released its earnings results on Tuesday, August, 14th. The biopharmaceutical company reported ($0.43) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.43). View GTX's Earnings History.
When is GTX's next earnings date?
What price target have analysts set for GTXI?
2 brokerages have issued 12-month price objectives for GTX's stock. Their predictions range from $30.00 to $45.00. On average, they expect GTX's share price to reach $37.50 in the next twelve months. This suggests a possible upside of 97.7% from the stock's current price. View Analyst Price Targets for GTX.
What is the consensus analysts' recommendation for GTX?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GTX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GTX.
Are investors shorting GTX?
GTX saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 1,498,327 shares, an increase of 31.7% from the July 13th total of 1,138,090 shares. Based on an average trading volume of 122,881 shares, the short-interest ratio is currently 12.2 days. Approximately 21.3% of the shares of the company are sold short. View GTX's Current Options Chain.
Who are some of GTX's key competitors?
Some companies that are related to GTX include Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Nabriva Therapeutics (NBRV), Portola Pharmaceuticals (PTLA), Aimmune Therapeutics (AIMT), ACADIA Pharmaceuticals (ACAD), Insmed (INSM), Puma Biotechnology (PBYI), TESARO (TSRO), Allakos (ALLK), ARMO Biosciences (ARMO), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Myovant Sciences (MYOV) and Innoviva (INVA).
Who are GTX's key executives?
GTX's management team includes the folowing people:
- Dr. Robert James Wills Ph.D., Exec. Chairman (Age 64)
- Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 55)
- Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 69)
- Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 43)
- Dr. Diane C. Young, VP & Chief Medical Officer (Age 61)
Has GTX been receiving favorable news coverage?
Headlines about GTXI stock have been trending somewhat positive on Tuesday, according to Accern. Accern rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GTX earned a daily sentiment score of 0.15 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 41.07 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for GTX.
Who are GTX's major shareholders?
GTX's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Boxer Capital LLC (5.81%), FMR LLC (3.76%), BlackRock Inc. (1.73%), Point72 Asset Management L.P. (0.76%), Federated Investors Inc. PA (0.65%) and Renaissance Technologies LLC (0.34%). Company insiders that own GTX stock include Diane C Young, Henry Patton Doggrell, Jason T Shackelford, Marc Steven Hanover, Peak Foundation Pyramid and Robert James Wills. View Institutional Ownership Trends for GTX.
Which institutional investors are selling GTX stock?
GTXI stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC and FMR LLC. Company insiders that have sold GTX company stock in the last year include Diane C Young, Henry Patton Doggrell, Jason T Shackelford and Marc Steven Hanover. View Insider Buying and Selling for GTX.
Which institutional investors are buying GTX stock?
GTXI stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Federated Investors Inc. PA, Pendal Group Ltd, Citadel Advisors LLC, Strs Ohio, Bank of New York Mellon Corp and Renaissance Technologies LLC. Company insiders that have bought GTX stock in the last two years include Peak Foundation Pyramid and Robert James Wills. View Insider Buying and Selling for GTX.
How do I buy shares of GTX?
Shares of GTXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GTX's stock price today?
One share of GTXI stock can currently be purchased for approximately $18.97.
How big of a company is GTX?
GTX has a market capitalization of $441 million. The biopharmaceutical company earns $-30,430,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. GTX employs 27 workers across the globe.
How can I contact GTX?
GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]
MarketBeat Community Rating for GTX (NASDAQ GTXI)
MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
